title: [Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis].
abstract: The objective of study was to investigate the role of the polymorphisms and protein expression of CYP3A5 gene in the therapy and prognosis of acute leukemia (AL) patients, the polymorphisms of CYP3A5 gene and the expression of protein CYP3A5 were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and immunohistochemistry method respectively. The results showed that there were three CYP3A5 genotypes in the 88 cases, namely CYP3A5*1/*1, CYP3A5*1/*3 and CYP3A5*3/*3 with frequencies of 26%, 50% and 24%, respectively. There were no significant differences in clinic data between the three groups, but the expressions of CYP3A5 of three groups were (36.6+/-19.2)%, (7.8+/-9.2)%, (0.5+/-0.9)%, the OS were (11.6+/-2.1) months, (30.5+/-12.2) months, (52.3+/-8.5) months, and the DFS were (7.5+/-1.8), (27+/-15.8), (52.3+/-8.1) months, respectively (p<0.05). It is concluded that the polymorphism of CYP3A5 gene is not related with the morbidity of AL, but closely associated with the expression of CYP3A5 in AL patients, and the latter are closely associated with the chemotherapeutic effect and prognosis. CYP3A5 genotype may be used as a new predictor to the chemotherapeutic effect and prognosis in AL cases.
authors.affiliation: Department of Hematology, Renji Hospital Affiliated to Jiaotong University, Shanghai 200001, China.
authors.forename: Li-Jing
authors.initials: LJ
authors.lastname: Shen
authors.forename: Fang-Yuan
authors.initials: FY
authors.lastname: Chen
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.forename: Hai-Rong
authors.initials: HR
authors.lastname: Wang
authors.forename: Ji-Hua
authors.initials: JH
authors.lastname: Zhong
authors.forename: Jie-Ying
authors.initials: JY
authors.lastname: Han
authors.forename: Ren-Rong
authors.initials: RR
authors.lastname: Ouyang
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D051544:Cytochrome P-450 CYP3A / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis
chemical_list: C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A